Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ)
CNY 4.77
(-0.83%)
CNY 4.77
(-0.83%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 2.64 Billion | 2.42 Billion | 2.45 Billion | 2.36 Billion | 2.78 Billion | 2.66 Billion |
| Cost of Revenue | 1.28 Billion | 1 Billion | 911.46 Million | 819.52 Million | 1 Billion | 1.02 Billion |
| Gross Profit | 1.36 Billion | 1.41 Billion | 1.54 Billion | 1.54 Billion | 1.77 Billion | 1.64 Billion |
| Operating Expenses | 1.11 Billion | 1.24 Billion | 1.34 Billion | 1.34 Billion | 1.49 Billion | 1.37 Billion |
| Selling, General and Administrative Expenses | 820.37 Million | 942.81 Million | 1.07 Billion | 1.11 Billion | 1.25 Billion | 1.1 Billion |
| Research and Development Expenses | 153.53 Million | 142.89 Million | 120.38 Million | 86.94 Million | 108.02 Million | 119.76 Million |
| Other Expenses | -17.37 Million | 10.82 Million | -986.83 Thousand | 351.98 Thousand | 181 Thousand | -1.51 Million |
| Cost and Expenses | 2.34 Billion | 2.25 Billion | 2.25 Billion | 2.16 Billion | 2.5 Billion | 2.39 Billion |
| Operating Income | 298.48 Million | 178.52 Million | -590.99 Million | 240.77 Million | 326.59 Million | -321.14 Million |
| Interest Expense | 30.39 Million | 26.93 Million | 20.44 Million | 10.16 Million | 2.4 Million | 1.54 Million |
| Income Tax Expense | 55.94 Million | -11.46 Million | 17.6 Million | 35.35 Million | 33.74 Million | 37.27 Million |
| Earnings before Tax | 290.35 Million | 189.35 Million | -591.98 Million | 241.12 Million | 326.77 Million | -322.65 Million |
| Net Income | 231.86 Million | 204.6 Million | -296.91 Million | 209.36 Million | 292.82 Million | -359.97 Million |
| Earnings Per Share Basic | 0.19 | 0.17 | -0.25 | 0.18 | 0.25 | -0.30 |
| Earnings Per Share Diluted | 0.19 | 0.17 | -0.25 | 0.18 | 0.25 | -0.30 |
| Weighted Average Shares Outstanding | 1.22 Billion | 1.18 Billion | 1.18 Billion | 1.18 Billion | 1.18 Billion | 1.18 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.22 Billion | 1.18 Billion | 1.18 Billion | 1.18 Billion | 1.18 Billion | 1.19 Billion |
| Gross Margin | 0.52 | 0.58 | 0.63 | 0.65 | 0.64 | 0.62 |
| EBIT Margin | 0.20 | 0.19 | 0.18 | 0.17 | 0.17 | 0.17 |
| Profit Margin | 0.09 | 0.08 | -0.12 | 0.09 | 0.11 | -0.13 |
| EBITDA | 528.99 Million | 340.61 Million | -409.89 Million | 407.06 Million | 473.14 Million | -186.79 Million |
| Earnings Before Tax Margin | 0.11 | 0.07 | -0.24 | 0.10 | 0.12 | -0.12 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 562.26 Million | 623.61 Million | 809.39 Million | 664.76 Million | 2.64 Billion | 654.46 Million |
| Cost of Revenue | 270.24 Million | 271.87 Million | 396.37 Million | 356.19 Million | 1.23 Billion | 303.64 Million |
| Gross Profit | 292.02 Million | 351.73 Million | 413.02 Million | 308.57 Million | 1.41 Billion | 350.82 Million |
| Operating Expenses | 208.77 Million | 262.67 Million | 290.67 Million | 292.17 Million | 1.16 Billion | 275.18 Million |
| Selling, General and Administrative Expenses | 287.59 Million | 150.94 Million | 264.38 Million | 78.52 Million | - | 320.62 Million |
| Research and Development Expenses | 31.07 Million | 31.17 Million | 33.12 Million | 49.91 Million | - | 35.69 Million |
| Other Expenses | -109.89 Million | -616.77 Thousand | -3.46 Million | -3.29 Million | -8.13 Million | -591.24 Thousand |
| Cost and Expenses | 479.01 Million | 534.55 Million | 687.04 Million | 648.37 Million | 2.4 Billion | 578.82 Million |
| Operating Income | 97.28 Million | 103.23 Million | 146.69 Million | 17.04 Million | 298.48 Million | 96.67 Million |
| Interest Expense | 5.57 Million | 5.18 Million | 7.33 Million | 7.96 Million | 29.56 Million | 7.27 Million |
| Income Tax Expense | 10.49 Million | 9.37 Million | 20.92 Million | 34.12 Million | 55.94 Million | 5.29 Million |
| Earnings before Tax | 96.86 Million | 102.61 Million | 143.22 Million | 13.75 Million | 290.35 Million | 96.08 Million |
| Net Income | 85.12 Million | 93.97 Million | 122.5 Million | -19.97 Million | 231.86 Million | 90.95 Million |
| Earnings Per Share Basic | 0.07 | 0.08 | 0.10 | -0.02 | - | 0.08 |
| Earnings Per Share Diluted | 0.07 | 0.08 | 0.10 | -0.02 | - | 0.08 |
| Weighted Average Shares Outstanding | 1.18 Billion | 1.18 Billion | 1.22 Billion | 1.28 Billion | 1.22 Billion | 1.18 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.18 Billion | 1.18 Billion | 1.22 Billion | 1.28 Billion | 1.22 Billion | 1.18 Billion |
| Gross Margin | 0.52 | 0.56 | 0.51 | 0.46 | 0.53 | 0.54 |
| EBIT Margin | 0.18 | 0.18 | 0.19 | 0.06 | - | 0.16 |
| Profit Margin | 0.15 | 0.15 | 0.15 | -0.03 | 0.09 | 0.14 |
| EBITDA | 102.43 Million | 112.73 Million | 152.37 Million | 41.38 Million | - | 106.74 Million |
| Earnings Before Tax Margin | 0.17 | 0.17 | 0.18 | 0.03 | 0.11 | 0.15 |
PNLF
5946
TMAS
ORBTEXP
RECO
PTM